ByTrending Posts
How Did Merck’s 2025 Deals Strengthen Its Pipeline…
In 2025, Merck pursued a series of high-impact collaborations, acquisitions, and licensing agreements to expand its portfolio, enhance…
Did Merck’s 2025 Strategies, Deals, and Pipeline Strength…
Merck concluded 2025 with a strong performance across its pharmaceuticals, vaccines, and oncology segments, demonstrating resilience, strategic focus,…
Did AstraZeneca’s 2025 Deals Lay the Groundwork for…
In 2025, AstraZeneca executed a series of strategic collaborations, partnerships, and selective acquisitions designed to strengthen its pipeline,…
Can AstraZeneca’s 2025 Execution Propel It to Leadership…
AstraZeneca concluded 2025 as a company demonstrating resilient performance, focused execution, and continued innovation across its pharmaceuticals and…
How Did Sanofi’s 2025 Deals Shape Its Strategy…
In 2025, Sanofi pursued a series of strategic collaborations, acquisitions, and licensing agreements aimed at strengthening its core…
What Lessons from Sanofi’s 2025 Execution Signal Its…
Sanofi concluded 2025 with a combination of solid portfolio performance, strategic execution, and continued innovation across its pharmaceuticals,…
How Did Roche’s 2025 Deals Shape Its Strategy…
In 2025, Roche executed a series of focused deals and collaborations designed to strengthen its scientific platforms, expand…
How Did Roche Navigate 2025 and What Lies…
Roche concluded 2025 as a company demonstrating resilient performance, strategic focus, and continued innovation across its pharmaceuticals and…
How Did Johnson & Johnson’s 2025 Deals Shape…
New Brunswick, NJ — In 2025, Johnson & Johnson executed a series of strategic collaborations, acquisitions, and partnerships…
Trending Posts
Latest Stories
Can AbbVie’s 2025 Earnings Prove Its Post-Humira Portfolio Is Built for the Next Decade?
Late January 2026 | Full-Year 2025 Earnings Preview | Biopharma Growth Strategy AbbVie is set…
Will Johnson & Johnson’s 2025 Earnings Reinforce Confidence in Its Pharma-Led Growth Engine?
Late January 2026 | Full-Year 2025 Earnings Preview | Diversified Pharma Outlook Johnson & Johnson…
Can Pfizer’s 2025 Earnings Reignite Confidence in Its Post-COVID Portfolio and Late-Stage Pipeline?
Late January 2026 | Full-Year 2025 Earnings Preview | Big Pharma Strategy Reset Pfizer is…
Will Novartis’ January 2026 Earnings Validate the Strength of Its Focused Portfolio and Late-Stage Pipeline?
January 30, 2026 | Full-Year 2025 Earnings Preview | Innovative Medicines Outlook Novartis is scheduled…
Gallery
